{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T01:50:14Z","timestamp":1780451414173,"version":"3.54.1"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"50","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1097\/md.0000000000009202","type":"journal-article","created":{"date-parts":[[2017,12,13]],"date-time":"2017-12-13T13:45:18Z","timestamp":1513172718000},"page":"e9202","source":"Crossref","is-referenced-by-count":9,"title":["Infliximab associated with life-threatening lung infection in a patient with Behcet disease with intestinal and hematopoietic system involvement"],"prefix":"10.1097","volume":"96","author":[{"given":"Yong","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-fen","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Fei","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-qin","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-long","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-89-20210226","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/jdv.12107","article-title":"The International Criteria for Behcet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria","volume":"28","author":"Davatchi","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R2-89-20210226","first-page":"286857","article-title":"Off-label uses of anti-TNF therapy in three frequent disorders: Beh\u00e7et's disease, sarcoidosis, and noninfectious uveitis","volume":"2013","author":"S\u00e1nchezcano","year":"2013","journal-title":"Mediators Inflamm"},{"key":"R3-89-20210226","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jaut.2015.06.005","article-title":"Efficacy of anti-TNF alpha in severe and\/or refractory Behcet's disease: multicenter study of 124 patients","volume":"62","author":"Vallet","year":"2015","journal-title":"J Autoimmun"},{"key":"R4-89-20210226","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/j.gastro.2003.10.047","article-title":"The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients","volume":"126","author":"Colombel","year":"2004","journal-title":"Gastroenterology"},{"key":"R5-89-20210226","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nrrheum.2012.156","article-title":"Differential diagnosis and management of Behcet syndrome","volume":"9","author":"Ambrose","year":"2013","journal-title":"Nat Rev Rheumatol"},{"key":"R6-89-20210226","first-page":"35","article-title":"Pi in traditional Chinesemedicine refers to pancreas while not spleen","volume":"8","author":"Yong","year":"2017","journal-title":"Negative"},{"key":"R7-89-20210226","first-page":"493","article-title":"Intestinal pathological changes in Behcet's disease: a clinical retrospective study","volume":"44","author":"Yong","year":"2017","journal-title":"Fudan Univ J Med Sci"},{"key":"R8-89-20210226","first-page":"365","article-title":"Clinical features of intestinal Beh\u00e7et's disease associated with myelodysplastic syndrome and trisomy 8","volume":"69","author":"Kawano","year":"2015","journal-title":"Acta Med Okayama"},{"key":"R9-89-20210226","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1159\/000355341","article-title":"Refractoriness of intestinal Beh\u00e7et's disease with myelodysplastic syndrome involving trisomy 8 to medical therapies\u2014our case experience and review of the literature","volume":"88","author":"Toyonaga","year":"2013","journal-title":"Digestion"},{"key":"R10-89-20210226","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/rheumatology\/kep126","article-title":"Effects of anti-TNF-alpha antibody infliximab in refractory entero-Behcet's disease","volume":"48","author":"Iwata","year":"2009","journal-title":"Rheumatology"},{"key":"R11-89-20210226","first-page":"1833","article-title":"Efficacy of infliximab in intestinal Behcet's disease: a Korean multicenter retrospective study","volume":"19","author":"Lee","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"R12-89-20210226","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3324\/haematol.2011.044347","article-title":"Value of infliximab (Remicade\u00ae) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group","volume":"97","author":"Baron","year":"2012","journal-title":"Haematologica"},{"key":"R13-89-20210226","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.beha.2013.09.003","article-title":"Myelodysplastic Syndromes (MDS) and autoimmune disorders (AD): cause or consequence?","volume":"26","author":"Braun","year":"2013","journal-title":"Best Pract Res Clin Haematol"},{"key":"R14-89-20210226","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1080\/10428190400027829","article-title":"Infliximab chimeric antitumor necrosis factor-a monoclonal antibody as potential treatment for myelodysplastic syndromes","volume":"46","author":"Stasi","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"R15-89-20210226","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/leu.2015.69","article-title":"Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes","volume":"29","author":"Ga\u00f1\u00e1n-G\u00f3mez","year":"2015","journal-title":"Leukemia"},{"key":"R16-89-20210226","doi-asserted-by":"crossref","first-page":"E280","DOI":"10.1002\/ajh.24333","article-title":"Autoimmune diseases and myelodysplastic syndromes","volume":"91","author":"Komrokji","year":"2016","journal-title":"Am J Hematol"},{"key":"R17-89-20210226","doi-asserted-by":"crossref","first-page":"S127","DOI":"10.1016\/S0145-2126(15)30256-3","article-title":"255 response to thalidomide and cyclosporine in patients with lower-risk myelodysplastic syndrome without isolated del(5q)","volume":"39","author":"Wang","year":"2015","journal-title":"Leuk Res"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000009202","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:47:19Z","timestamp":1620960439000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201712150-00089"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":17,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000009202","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]}}}